Figure 1.
The sex-specific relative survival (RS) of R-CHOP21-treated older (>60 years) patients with DLBCL in The Netherlands, from 2014 to 2020. Sex-specific RS is shown for the following age categories at diagnosis: (A) >60 years, (B) from 61 to 70 years, (C) from 71 to 80 years, and (D) >80 years. The tables present the projected 3- and 5-year RS with associated 95% confidence intervals and the number at risk according to sex. The P value is derived from the likelihood ratio test that compares the model with years of follow-up and sex with the model containing only years of follow-up. The median follow-up for 2115 (66%) patients alive at the end of follow-up was 47.3 months (interquartile range, 28.2-69.5 months). CI, confidence interval.

The sex-specific relative survival (RS) of R-CHOP21-treated older (>60 years) patients with DLBCL in The Netherlands, from 2014 to 2020. Sex-specific RS is shown for the following age categories at diagnosis: (A) >60 years, (B) from 61 to 70 years, (C) from 71 to 80 years, and (D) >80 years. The tables present the projected 3- and 5-year RS with associated 95% confidence intervals and the number at risk according to sex. The P value is derived from the likelihood ratio test that compares the model with years of follow-up and sex with the model containing only years of follow-up. The median follow-up for 2115 (66%) patients alive at the end of follow-up was 47.3 months (interquartile range, 28.2-69.5 months). CI, confidence interval.

Close Modal

or Create an Account

Close Modal
Close Modal